$DOX

Amdocs Ltd

  • NASDAQ
  • Technology Services
  • Information Technology Services
  • Professional, Scientific, and Technical Services
  • Custom Computer Programming Services

PRICE

$91.03 -

Extented Hours

VOLUME

667,857

DAY RANGE

90.62 - 91.795

52 WEEK

77.6 - 97.76

Join Discuss about DOX with like-minded investors

profile
@dros #droscrew
recently

Disney $DIS Trade Desk $TTD Unity Software $U Robinhood $HOOD Nutrien $NTR Manulife $MFC Steris $STE Amdocs $DOX Ritchie Bros. $RBA $FLEX $JAZZ Genpact $G Pan American Silver $PAAS AppLovin $APP

134 Replies 11 👍 14 🔥

profile
@NoobBot #Crypto4Noobs
recently

Buzzfeed’s Bored Ape NFT dox: Danger to crypto or journalistic integrity? https://cointelegraph.com/news/buzzfeed-s-bored-ape-nft-dox-danger-to-crypto-or-journalistic-integrity

42 Replies 8 👍 12 🔥

profile
@NoobBot #Crypto4Noobs
recently

Daniele Sestagalli discusses Wonderland’s future after QuadrigaCX co-founder dox https://cointelegraph.com/news/daniele-sestagalli-discusses-wonderland-s-future-after-quadrigacx-co-founder-dox

79 Replies 13 👍 10 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

U.S. futures are holding steady, only moderately lower from yesterday’s closing all-time highs for the major averages as investors brace for the FOMC meeting, with results expected tomorrow afternoon. Bitcoin prices surging to highs, up over 4% around $63,400 in another broad spike for crypto assets; Ethereum +3.25% at $4,450. House Speaker Pelosi is planning to go ahead with plans to vote this week on President Biden’s two bills even though Democratic moderates are echoing Senator Manchin’s complaints that they don’t know full cost & economic impact. In corporate news, JNJ, TEVA, ENDP and ABBV win the first case for pharmaceutical companies in the four-year litigation over the drugs in a $50B opioid litigation case. In commodity prices, gold holds below $1,800, oil is little changed around $84 per barrel and Wheat hit $8.00 a bushel Monday, highest levels since 2012 as world reserves declined following extreme weather. The Aussie dollar drops and the curve bull steepens after the RBA scraps its April 2024 yield target and signals openness to earlier rate hikes. Tesla $TSLA falls over 4%, is falling off a record high close of $1,208.59 – follows tweet from CEO Musk overnight saying there has been no contract signed yet with Hertz and that the Hertz deal has zero effect on Tesla’s economic. Wall Street’s main indexes notched record closing highs again on Monday, adding to the big totals in October as Tesla $TSLA shares surged and the energy sector gained on rising oil prices while investors looked ahead to a major Federal Reserve meeting later in the week. The Dow Jones Industrial Average briefly eclipsed 36,000 points for the first time before slipping just below. Along with the barrage of earnings again this week, the Federal Reserve is expected to approve plans to scale back its $120 billion monthly bond-buying program on Wednesday. The small-cap Russell 2000 index was a standout, rising 2.7% for its biggest daily percentage gain since late August. Economic data was mixed as the ISM U.S. manufacturing activity slowed in October, with all industries reporting record-long lead times. In Asian markets, The Nikkei Index slipped -0.43% to 29,520, the Shanghai Index dropped -1.1% to 3,505, and the Hang Seng Index fell -0.22% to 25,099. In Europe, the German DAX is up +0.4% at 15,875, while the FTSE 100 declines around -0.6% below 7,250. Events Calendar for Today · 7:45 AM ET ICSC Weekly Retail Sales · 8:55 AM ET Johnson/Redbook Weekly Sales Earnings Calendar: · Earnings Before the Open: AME, APO, ARCB, AVNS, BBGI, BCC, BHC, BLD, BLMN, CEIX, CLW, CMI, COP, CRSR, CTLT, DD, EL, EPD, ESPR, ETN, EXLS, EXPD, EXTR, GNRC, GPN, HEES, HEP, HSC, HSIC, IART, IDXX, INCY, IPGP, IT, KKR, LCII, LDOS, LEA, LGIH, LPX, MIME, MLM, MMP, MPC, MPLX, MYGN, NRZ, NXST, NYMT, OMCL, PFE, PINC, RL, ROK, SABR, SAGE, SEE, TMX, TNC, UAA, VAL, WEC, WLK, XHR, XYL ZBRA · Earnings After the Close: ACT, AFG, AIZ, AKAM AMGN, ANDE, ATVI, AWK, AYX, BFAM, BGFV, BKH, BRY, BXC, CASA, CDK, CERS, CHK, COUR, CRK, CSLT, CZR, DCO, DCPH, DEI, DENN, DOX, DRRX, DVN, EGHT, EIX, ENLC, EXAS, EXEL, FMC, FNF, FRSH, GAIN, GNW, GPOR, HALO, HCC, HLF, HRB, HURN, INFI, INSP, KAI, KAMN, KAR, LPI, LSCC, LSI, LYFT, MANT, MDLZ, MG, MGNX, MOD, MRCY, MTCH, NP, NSA, OKE, OVV, PAA, PAGP, PAYC, PKI, PRO, PRTS, PRU, RAMP, RARE, RCKY, RM, RRR, SGRY, SKY, SRC, STE, TCS, TMUS, TVTY, UIS, UNM, VECO, VOYA, VRSK, WTTR, WU, ZG Other Key Events: · China Caixin Services PMI for October · Wolfe Research Wealth Symposium, 11/2-11/3 $virtual · Senator Manchin says he is prepared to support a Build Back Better plan that combats inflation, is fiscally responsible, and will create jobs. The plan the House is finalizing meets those tests-it is fully paid for, will reduce the deficit, and brings down costs for health care, child care, elder care, and housing

101 Replies 10 👍 7 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Healthcare Moderna ($MRNA) Q2 EPS $6.46 vs. est. $6.04; Q2 revs $4.4B vs. est. $4.28B; expects dose capacity for its covid-19 vaccine in fy 2021 to be between 800 mln and 1 bln doses; advance purchase agreements signed for expected product sales of $20 bln in 2021, including sales already recorded in 6 months ended June 30; signed agreements for $12 bln worth of sales for covid-19 vaccine in 2022, option for about $8 bln more; continue to expect $450 mln -$550 mln of capital investments for 2021 Cigna ($CI) Q2 adj EPS $5.24 vs. est. $4.96; Q2 revs $43.13B vs. est. $41.31B; pharmacy customer base at Q2 grew to 101.9M, an organic increase of 3.1M year to date; total medical customer base at Q2 was 17M, an increase of 279,000 customers YTD; Q2 profit overall fell -16% hurt by higher medical costs; backs year EPS but ups its rev guidance to at least $170B from $166B Nevro ($NVRO) slides after withdrawing FY forecast on COVID-19 concerns and guided Q3 sales between $90M-$93M which is below analyst estimates of $114.7M Regeneron Pharma ($REGN) phase 3 Trial of Libtayo combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer Abiomed ($ABMD) Q1 adj EPS $1.10 vs. est. $1.05; Q1 revs $252.6M vs. est. $240.91M; raises FY22 revenue view to $1.03B-$1.05B from prior $990M-$1.03B (22%-24% growth); expects its fiscal year 2022 non-GAAP operating margin to be in the range of 24% to 26% Amedisys ($AMED) announces new $100M share repurchase program; Q2 adj EPS $1.69 vs. est. $1.67; Q2 revs $564.2M vs. est. $566.19M; guides 2021 adj EPS $6.37-$6.49 vs. est. $6.96; sees 2021 adj net service revenue $2.23B-$2.245B. Evolent Health ($EVH) 2Q EPS ($0.11) vs est. ($0.04) on revs $222.1Mm vs est. $216.9Mm; guides 3Q revs $215-230Mm vs est. $217.7Mm, sees FY revs $870-900Mm vs est. $870.8Mm; announces agreement to acquire Vital Decisions outstanding equity interests for aggregate price up to $130Mm, says transaction is accretive to EBITDA/share before synergies McKesson ($MCK) Q1 adj EPS $5.56 vs. est. $4.15; Q1 revs $62.7B vs. est. $59.99B; raises FY22 adj EPS view to $19.80-$20.40 from prior view $18.85-$19.45 (est. $19.23) 1life Healthcare, Inc. ($ONEM) Q2 EPS loss (-$0.30) vs. est. loss (-$0.20); Q2 revs $120.4M vs. est. $115.7M; sees Q3 revs $113M-$120M vs. est. $118M; sees year revs $475M-$485M vs. est. $482.3M; Membership count as of quarter-end was 621,000 compared to 475,000, a 31% increase; Adjusted EBITDA was positive $6.9 million, or 6% of net revenue Sarepta Therapeutics ($SRPT) Q2 non-GAAP EPS loss (-$1.52) vs. est. loss (-$1.26); net product sales for q2 reached $141.8 mln, a 27% increase over same quarter of prior year; raises full-year product revenue guidance by nearly $30 mln to between $565 mln to $575 mln Tandem Diabetes ($TNDM) 2Q revs $172.1Mm vs est. $143.4Mm; guides FY sales $670-685Mm vs est. $637Mm; guides FY adj EBITDA mgn about 15% vs est. 13.5% Industrials & Materials Albemarle ($ALB) Q2 adj EPS $0.89 vs. est. $0.83; Q2 revs $773.9M vs. est. $788.6M; qtrly lithium net sales of $320.3 mln increased $36.6 mln yoy primarily driven by higher volumes; full-year 2021 net sales guidance improved vs previous guidance primarily due to increased lithium sales, improving catalysts trends – sees year sales $3.3B-$3.4B vs. est. $3.24B Hillenbrand ($HI) 3Q adj EPS $0.85 vs est. $0.76 on revs $695Mm; guides 4Q adj EPS $0.82-0.92 vs est. $0.85, sees 4Q revs $713-738Mm vs est. $709.1Mm Maxar Technologies ($MAXR) 2Q EPS $0.60 vs est. $0.14 on revs $473Mm vs est. $441.5Mm Summit Materials ($SUM) 2Q EPS $0.48 vs est. $0.52 on revs $618.5Mm vs est. $647.1Mm; no change to FY guide Valvoline ($VVV) Q3 adj EPS $0.55 vs. est. $0.45; Q3 revs $792M vs. est. $745.32M; Q3 retail Services system-wide same-store sales grew 40.5%; Q3 same-store sales rose 27%; sees FY sales growth 25%-26% and FCF $250M-$270M Media & Telecom Fox Corp. ($FOXA) Q4 adj EPS $0.65 vs. est. $0.57; Q4 revs $2.89B vs. est. $2.75B; raises semi-annual dividend to 24c; cable network programming reported quarterly segment revenues of $1.40B, an increase of $128M; affiliate revenues increased 10% with 16% growth at the television segment and 6% growth at the cable network programming segment in q4 Roku Inc. ($ROKU) Q2 EPS 52c vs est. 13c on revs $645M vs est. $618.4M, average rev per user $36.46 (+46% YoY), active accounts 55.1M vs est. 55.8M; at midpoint of Q3 guidance, sees revs $675M-$685M vs est. $645M, gross profit $315M-$325M, adj EBITDA $60M-$70M, net income (-$3M)-$7M, anticipates sequential increases in operating expenses in 2H from investments in headcount, product development, and sales & marketing Technology Amdocs Ltd. ($DOX) 3Q adj EPS $1.35 vs est. $1.18 on revs $1.066B vs est. $1.06B; guides 4Q adj EPS $1.13-1.19 vs est. $1.28, sees 4Q revs $1.065-1.105B vs est. $1.087B Booking Holdings ($BKNG) 2Q adj EPS ($2.55) vs est. ($2.04) on revs $2.2B vs est. $1.9B, encouraged by sequential improvement in booking trends with 2Q room nights +59% vs 1Q; said in in q2, we saw the first sequential increase in the number of properties on booking.com and lowest number of properties coming off of our platform since the onset of the covid-19 pandemic DXC Technology ($DXC) Q1 adj EPS $0.84 vs. est. $0.74; Q1 revs $4.14B vs. est. $4.11B; Q2 guidance falls short of views but backs year EPS view $3.45-$3.65 vs. est. $3.56 and backs FY22 revenue view $16.6B-$16.8B (est. $16.74B); Bookings of $4.6 billion and book-to-bill ratio of 1.12x in Q1 FY22 Electronic Arts ($EA) Q1 EPS $0.71 vs. est. $0.62; Q1 net bookings $1.336B vs. est. $1.28B; sees Q2 EPS roughly $0.36 vs. est. $1.07; sees Q2 net bookings $1.725B vs. est. $1.62B; raises FY22 EPS view to $1.58 from $1.34 and ups FY21 bookings view to $7.4B from $7.3B Fastly Inc. ($FSLY) shares fall -18%; Q2 adj EPS ($$0.15) vs est. ($0.17) on revs $85.03M vs est. $85.7M, sees Q3 EPS loss (21c)-(18c) vs est. (18c) on revs $82M-$85M vs est. $97.9M, and forecasts FY EPS (65c)-(57c) vs est. (43c) on revs $340M-$350M vs est. $382.5M GoDaddy ($GDDY) Q2 EPS $0.27 vs. est. $0.32; Q2 revs $931.3M vs. est. $919.7M; total bookings of $1.055B, up 12.7% year over year, or 10.6% on a constant currency basis; Domains revenue of $436.7 million, up 18.2% yoy; Hosting and presence revenue of $318.5 million, up 9.0% yoy; Business applications revenue of $176.1 million, up 21.8% yoy; sees year revs $3.75B, in-line HubSpot ($HUBS) 2Q adj EPS $0.43 vs est. $0.32 on revs $310.8Mm vs est. $296Mm; guides 3Q adj EPS $0.42-0.44 vs est. $0.39, sees 3Q revs $325-327Mm vs est. $318.7Mm; guides FY revs $1.268-1.272B vs est. $1.244B MercadoLibre ($MELI) Q2 EPS $1.37 vs est. $0.19 on revs $1.7B vs est. $1.48B with commerce revs +96.4% YoY and fintech revs +88.9%; unique active users 75.9M in quarter (+47.4% YoY), total payment volume through Mercado Pago topped $17.5B (+56.3% in USD), gross merchandise volume $7B (+39.2% in USD) Ping Identity ($PING) 2Q adj EPS $0.11 vs est. $0.04 on revs $78.9Mm vs est. $66.1Mm; guides 3Q revs $65-70Mm vs est. $65.1Mm, sees 3Q total ARR $286-288Mm; guides FY revs $278-285Mm vs est. $269.3Mm, sees FY total ARR $304-306Mm Qorvo ($QRVO) Q1 EPS $2.83 vs. est. $2.45; Q1 revs $1.11B vs. est. $1.08B; sees Q2 EPS $3.24 at midpoint vs. est. $3.02; sees Q2 revenue $1.24B-$1.26B vs. est. $1.21B Trimble Inc. ($TRMB) Q2 adj EPS $0.72 vs. est. $0.59; Q2 revs $945.3M vs. est. $867.8M; sees FY21 adj EPS $2.45-$2.65 vs. est. $2.45; sees FY21 adjusted revenue $3.55B-$3.65B vs. est. $3.48B; Q2 annualized recurring revenue (ARR) was $1.35 billion, up 11% yoy Western Digital ($WDC) 4Q adj EPS $2.16 vs est. $1.51 on revs $4.9B vs est. $4.55B; guides 1Q revs $4.9-5.1B vs est. $4.9B, sees 1Q adj EPS $2.25-2.55 vs est. $2.05

118 Replies 7 👍 9 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Wednesday, August 4, 2021 Futures Up/Down % Last Dow -25.00 0.07% 34,973 S&P 500 -1.25 0.04% 4,413 Nasdaq 11.50 0.08% 15,058 U.S. S&P futures are flat heading into the trading day, looking to build on record highs from Tuesday as positive earnings boost U.S and European stocks while worries over China’s gaming and technology crackdown ease, helping lift those markets. Risk sentiment improves across Asia as Chinese and Hong Kong stocks push higher on tech recovery and solid Caixin PMI data. In Asian markets, The Nikkei Index fell -57 points to 27,854, the Shanghai Index rose 29 points to 3,477 and the Hang Seng Index jumped 231 points to settle at 26,426. In Europe, the German DAX is climbing around 125 points to 15,680, while the FTSE 100 is up 0.4% to 7,135. Chinese Jul Caixin Services PMI beat: 54.9 vs 50.6 consensus. Some also see the spread of the Covid-19 delta variant as delaying rather than stopping the economic recovery. The New York Times reported overnight that the FDA plans to give full approval to Pfizer (PFE) and BioNTech (BNTX) coronavirus vaccine by the start of the next month. Earnings season has been strong with about 87% of S&P 500 companies reporting earnings and revenue beats, according to FactSet. Just under 70% of the S&P 500 now has reported earnings. The S&P 500 closed at record highs with gains in Apple and healthcare stocks, as concerns over a surge in the Delta variant of the coronavirus was put to the back-burner, overshadowed by continued upbeat corporate earnings. Ten of the 11 S&P indexes traded higher, with energy stocks rebounding after getting hit by a dip in oil prices. Market Closing Prices Yesterday The S&P 500 Index gained 35.99 points, or 0.82%, to 4,423.15 The Dow Jones Industrial Average rose 278.24 points, or 0.80%, to 35,116.40 The Nasdaq Composite climbed 80.23 points, or 0.55%, to 14,761.29 The Russell 2000 Index advanced 8.09 points, or 0.36% to 2,223.58 Events Calendar for Today 7:00 AM ET MBA Mortgage Applications Data 8:15 AM ET ADP Employment Change for July…est. 695K 9:45 AM ET Markit Composite PMI, July-F 9:45 AM ET Markit Services PMI, July-F 10:00 AM ET ISM Non-Manufacturing Services PMI for July…est. 60.5 10:30 AM ET Weekly DOE Inventory Data Earnings Calendar: Earnings Before the Open: ABC, AEIS, ALE, APO, ASTE, BCOR, BDC, BGCP, BWA, CDW, CLVS, CLH, CLW, CMLS, CRL, CSII, DNOW, DOC, EDIT, EMR, ETR, EXC, FLOW, FUN, GEL, GM, HDSN, HFC, HZNP, IONS, JLL, KHC, LL, MAC, MKL, MPC, MPLX, MTOR, NI, NYT, ODP, RCL, SBGI, SGRY, SITE, SMG, SPR, SUP, TGI, TUP, TXMD, UTHR, VCEL, VMC, WLL Earnings After the Close: ACAD, ACLS, ADPT, ADTN, AGL, ALB, ALL, AMED, ANGI, ANSS, APA, ATO, AXGN, BBSI, BE, BFAM, BKNG, BOOT, CCMP, CDAY, CENX, CHNG, CMP, CPS, DGII, DOX, DVAX, DXC, EA, EGHT, ELF, EMKR, EOG, ETSY, EVH, FLT, FOXA, FSLY, FTDR, GDDY, GNK, HI, HUBS, IAC, INGN, IVR, JACK, LESL, LNC, LPI, LUMN, MAXR, MBI, MCK, MED, MET, MGM, MOD, MRO, MTG, NUS,NVRO, ONEM, PARR, PDCE, $PING, PLYA, QRVO, QTWO, RCII, REGI, RGR, RMAX, RNWK, EOKU, RPD, $RVLV, RYN, SBRA, SMSI, SUM, T$NDM, TPC, TTGT, TVTY, TWNK, TWO, TXG, $UBER, UHAL, VVV, VZIO, WDC, WU, YELL Other Key Events: Jefferies Industrials Conference (virtual), 8/3-8/4 Piper Wealth Management Forum (virtual), 8/3-8/6 Macro Up/Down Last Nymex -0.34 70.22 Brent -0.18 72.23 Gold 3.30 1,813.75 EUR/USD -0.0008 1.1856 JPY/USD 0.13 109.17 10-Year Note +0.008 1.182% Sector News Breakdown Consumer Caesar’s Entertainment ($CZR) Q2 EPS $0.34 vs. est. loss (-$0.26); Q2 revs $2.5B vs. est. $2.27B; Q2 same-store Adjusted EBITDA was $1B versus (-$131M) for the comparable prior-year period; Company posted all-time records in quarterly Adjusted EBITDA and Adjusted EBITDA margin. Denny’s ($DENN) Q2 adj EPS $0.18 vs. est. $0.11; Q2 revs $106.2M vs. est. $98.1M; Q2 domestic system-wide same-store sales decreased 1.2% compared to the equivalent fiscal period in 2019, including a 1.5% decrease at domestic franchised restaurants and a 1.9% increase at company restaurants. Herbalife ($HLF) Q2 adj EPS $1.52 vs. est. $1.29; Q2 revs $1.55B vs. est. $1.57B; Q2 adjusted EBITDA of $262.1M; raises FY21 EPS view to $4.70-$5.10 from $4.65-$5.05 (est. $4.93); sees FY net sales growth to be in a range of 8.5% to 12.5%, lowering the midpoint by 150 basis points compared to prior full year 2021 guidance. Host Hotels ($HST) Q2 adj FFO $0.12 vs. est. $0.04; Q2 revs $649M vs. est. $606.58M; said RevPAR reached nearly $100 for the quarter, which dramatically outperformed consensus RevPAR, with average room rates only 8.4% below our 2019 second quarter rates; not providing year guidance Hyatt ($H) 2Q adj EPS ($1.15) vs est. ($0.85) on comparable system-wide REVPAR $72.47, qtrly total revs $663Mm vs est. $686.9Mm; guides FY net rooms growth more than +6%, sees FY adj SG&A about $240Mm, sees FY CAPEX about $110Mm Energy Devon Energy ($DVN) Q2 adj EPS $0.60 vs est. $0.52 on revs $2.42B vs est. $2.35B, operating cash flow $1.1B, production for the quarter averaged 291k barrels/day; will pay total dividend of 49c/shr (11c fixed + 38c variable), a 44% increase from Q1; sees 3q production 566-594 mboe/d vs est. 564.80 mboe/d Occidental Petroleum ($OXY) Q2 adj EPS 32c vs est. 1c on revs $5.96B vs est. $5.92B, FCF $2B, cash flow from continuing operations $3.3B; said oil and gas results improved from Q1 due to higher commodity prices and sales volumes; executed debt tender offer and repaid over $3B of long-term debt in July ONEOK ($OKE) Q2 EPS $0.77 vs. est. $0.75; Q2 revs $3.39B vs. est. $3.03B; sees 2021 net income, adj earnings before interest, taxes, depreciation, amortization to be above midpoints of ranges provided on April 27, 2021 SunPower ($SPWR) Q2 adj EPS $0.06 vs. est. $0.04; Q2 revs $308.9M vs. est. $327.31M; guides Q3 revs $325M-$375M vs. est. $400.83M; sees Q3 GAAP net loss of $10 to $0 million and MW recognized of 125 MW to 150 MW; Q2 added 13,000 residential customers – residential bookings up 16 percent sequentially, 67 percent year-over-year (YoY) The American Petroleum Institute ($API) showed a draw of 879K barrels of oil for the latest week; gasoline inventories show a draw of 5.75M barrels, distillate inventories show a draw of 717K barrels and Cushing inventories show a build of 659K barrels W&T Offshore ($WTI) Q2 EPS $0.02 vs. est. $0.07; Q2 revs $132.8M vs. est. $122.38M; Q2 Production was 40,888 Boe/d or 3.7 MMBoe, an increase of 3% compared to 39,657 Boe/d in Q1 and down 3% versus 42,037 Boe/d in Q2 of 2020 Financials Assurant Inc. ($AIZ) Q2 operating EPS $2.99 vs. est. $2.45; Q2 revs $2.54B vs. est. $2.39B; continue to expect to grow eps, ex. catastrophes, by 10 to 14 percent for 2021 Fair Isaac ($FICO) Q3 non-GAAP EPS $3.38 vs. est. $2.76; Q3 revs $338M vs. est. $328.3M; Applications revenues, which include the company’s decision management applications and associated professional services, were $133.2 million in the third quarter, compared to $141.5 million in the prior year period, a decrease of 6% Genworth Financial ($GNW) Q2 adj EPS $0.38 vs. est. $0.22; Q2 revs $2.04B vs. est. $1.9B; planned IPO of Enact remains a key strategic objective for Genworth and is subject to market and other conditions, however because the company is in registration and subject to applicable publicity restrictions, is unable to comment further or provide any additional detail at this time. Green Dot ($GDOT) Q2 adj EPS $0.68 vs est. $0.43 on revs $369.4M vs est. $313.2M; sees FY21 adj EPS $2.13-$2.27 vs prev. $2.06-$2.15, revs $1.33B-$1.35B vs est. $1.28B Prudential ($PRU) Q2 adj EPS $3.79 vs. est. $3.02; qtrly book value per common share of $160.31 versus $165.53 per share for year-ago; qtrly adjusted book value per common share of $104.39 versus $92.07 per share for year-ago; qtr end assets under management of $1.730 trillion versus $1.605 trillion for year-ago; now expect to return a total of $11.0B to holders from $10.5B prior Tanger Outlets ($SKT) 2Q core FFO/shr $0.43 vs est. $0.28, portfolio occupancy was 93% on June 30 vs 91.7% on March 31, avg tenant sales productivity was $424/sq ft for 12 months ended June 30 +7.3% yr/yr; guides FY FFO/shr $1.52-1.59 vs est. $1.46 Unum Group (UNM) Q2 adj EPS $1.39 vs. est. $1.11; Q2 revs $2.99B vs. est. $2.96B; Full-year 2021 outlook increased; after-tax adjusted operating income per share now expected to decline 1%-3% relative to full-year 2020, compared to an expected decline of 5%-6% prior Verisk Analytics ($VRSK) Q2 adj EPS $1.17 vs. est. $1.33; Q2 revs $747.5M vs. est. $737.3M; Net cash provided by operating activities was $233.2 million, down 6.5% for the second quarter of 2021. Free cash flow, a non-GAAP measure, was $170.7 million, down 11.5% Healthcare Change Healthcare ($CHNG) shares fell over 7% on a report that the U.S. Dept. of Justice is considering a lawsuit to block the company’s $8B sale to UnitedHealth ($UNH) https://bit.ly/3yA4Etu Option Care Health ($OPCH) 18M share Spot Secondary priced at $20.25 Amgen Inc. ($AMGN) Q2 adj EPS $4.38 vs. est. $4.06; Q2 revs $6.5B vs. est. $6.43B; backs FY21 adj EPS view $16.00-$17.00 vs. est. $16.34; backs FY21 revenue view $25.8B-$26.6B vs. est. $26.04B Amid surge in new COVID-19 infections across U.S., the FDA plans to give full approval to Pfizer (PFE) – BioNTech (BNTX) coronavirus vaccine by the start of the next month, The New York Times reports The FDA classified the recent recall of some of Philips’ (PHG) ventilators as Class 1, or the most serious type of recall, saying the use of these devices may cause serious injuries or death – Reuters CVS Health ($CVS) Q2 adj EPS $2.42 vs. est. $2.06; Q2 revs $72.62B vs. est. $70.11B; raises FY21 adjusted EPS view to $7.70-$7.80 from $7.56-$7.68 (est. $7.66); sees FY21 cash flow from operations $12.5B-$13B DaVita Inc. (DVA) 2Q EPS $2.64 vs est. $2.17; says total US dialysis treatments for 2Q were 7,413497 (avg 95,045/day); guides FY adj EPS $8.80-9.40 vs est. $8.63, sees FY adj op income $1.8-1.875B vs est. $1.816B Inspire Medical ($INSP) 2Q EPS ($0.48) vs est. ($0.64) on revs $53Mm vs est. $43.9Mm; guides FY revs $210-213Mm vs est. $195.9Mm, sees FY gr mgn 85-86%, sees opening 48-52 new US medical centers per qtr for 2H Jazz Pharma ($JAZZ) Q2 adj EPS $3.90 vs. est. $3.42; Q2 revs $751.8M vs. est. $735.62M; reaffirms FY21 non-GAAP EPS view $13.40-$14.70 (est. $14.45) and also back FY21 revenue view $3.020B-$3.180B vs. est. $3.11B; as of June 30, cash, cash equivalents were $891.4 mln, and outstanding principal balance of co’s long-term debt was $7.1 bln

148 Replies 13 👍 8 🔥

profile
@CarlosH-carvan #ivtrades
recently

$DOX 75P Apr16th

80 Replies 12 👍 7 🔥

profile
@dros #droscrew
recently

Dox the shit out of those kids

68 Replies 12 👍 9 🔥

profile
@Jonove #droscrew
recently

interesting you mentioned DOX, read a good article about Tony Abbott, former PM of aus

44 Replies 8 👍 8 🔥

profile
@dros #droscrew
recently

wonder if the Forbes editor changed his number yet after the Kanye dox

111 Replies 14 👍 11 🔥

Key Metrics

Market Cap

10.84 B

Beta

0.70

Avg. Volume

779.81 K

Shares Outstanding

117.54 M

Yield

1.86%

Public Float

0

Next Earnings Date

2024-05-15

Next Dividend Date

2024-03-27

Company Information

amdocs is the market-leader in customer experience software solutions and services for the world’s largest communications, entertainment and media service providers. our portfolio powers the new world of customer experience™, where a wide array of innovative and personalized services are delivered seamlessly to end users, regardless of device or network. for more than 30 years, amdocs solutions, which include bss, oss, network control and optimization, coupled with our professional and managed services, have accelerated business value for our customers by streamlining complex operating environments, reducing costs and speeding time to market for new products and services. amdocs and our more than 24,000 employees serve customers in over 90 countries. listed on the nasdaq global select market, amdocs had revenue of $3.6 billion in fiscal 2014. amdocs: embrace challenge, experience success. for more information, visit amdocs at www.amdocs.com.

CEO: Shuky Sheffer

Website:

HQ: ,

Related News